Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021348 | 0.89 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3462883 | 0.85 | CYP11B1 (0.56) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL477609 | 0.82 | PDE3B (0.54) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL29526300 | 0.82 | PDE3B (0.54) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| Hydrochloric Acid SCHEMBL2362200 | 0.81 | PDE3B (0.53) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL24982282 | 0.78 | CHRNB2 (0.47) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL15985206 | 0.77 | NPC1 (0.50) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10552765 | 0.77 | CYP11B1 (0.40) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL9755420 | 0.75 | CYP11B1 (0.43) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL7015184 | 0.74 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | claimed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | claimed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | claimed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | claimed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | claimed |
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | TENAYA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-117897370-A | Heterocyclic compounds and their use | 凯悦施那有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4281450-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Syngenta Crop Protection AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| CN-116783193-A | Pesticidally active heterocyclic derivatives with sulfur containing substituents | 先正达农作物保护股份公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230097157-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| EP-4076448-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-2351744-B1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE | SHIONOGI & CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| WO-2010074807-A1 | 3, 4-DIHYDROQUINOLIN-2 ( 1H ) -ONE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | HDAC6, HDAC1, HDAC2 | NPC1 534/4885MAPK13 2540/4885MAPK12 3028/4885 |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | NPC1 3383/4885MAPK13 997/4885MAPK12 1841/4885 |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | NPC1 2745/4885MAPK13 3395/4885MAPK12 3236/4885 |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | NPC1 872/4885MAPK13 2705/4885MAPK12 2221/4885 |
| US-20230097157-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | KLKB1, F2, SERPINC1 | NPC1 3162/4885MAPK13 1095/4885MAPK12 2325/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | NPC1 2745/4885MAPK13 3395/4885MAPK12 3236/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | NPC1 2745/4885MAPK13 3395/4885MAPK12 3236/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | NPC1 749/4885MAPK13 2837/4885MAPK12 2391/4885 |
| US-20230183233-A1 | Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors | KLKB1, F2, SERPINC1 | NPC1 3162/4885MAPK13 1095/4885MAPK12 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.